VIDEO: Ocuphire partners with Viatris for marketing, commercialization of Nyxol eye drop
Click Here to Manage Email Alerts
NEW YORK — In this Healio Video Perspective from OSN New York, Mina Sooch, founder and CEO of Ocuphire Pharma, discusses the company’s partnership with Viatris for the marketing and commercialization of the Nyxol eye drop.
According to Sooch, Ocuphire is aiming to submit a new drug application to the FDA later this quarter for the reversal of mydriasis, the first indication for Nyxol. The ophthalmic solution is also under investigation for the treatment of presbyopia and night vision disturbances.
“2023 is set up to be another year of a lot of catalysts across our programs, with the potential commercialization of Nyxol and this partnership that we look forward to sharing more about and being a part of in the years ahead,” she said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts